Last reviewed · How we verify
NCT05254197: SOLOMON
SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)
trial in Brain Tumor, Primary in 3,000 participants. Currently enrolling.
31 December 2035
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 January 2001 |
| Primary completion | 31 December 2035 |
| Estimated completion | 31 December 2035 |
| Sites | 1 location across South Korea |
Conditions studied
- Brain Tumor, Primary — all drugs for Brain Tumor, Primary →
- Meningioma — all drugs for Meningioma →
- Schwannoma — all drugs for Schwannoma →
- Pituitary Adenoma — all drugs for Pituitary Adenoma →
Sponsor
Seoul National University Hospital
Who can join
18 and older, any sex, with Brain Tumor, Primary or Meningioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05254197
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Tumor, Primary
Currently open trials in the same condition.
- NCT06185686 — Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients · recruiting
- NCT06282562 — FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients · NA · recruiting
- NCT05831631 — Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors · recruiting
- NCT04427384 — Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) · recruiting
- NCT05775458 — Glutamate Excitotoxicity and Its Role in Glioblastoma Biology · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05254197 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 3 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254197.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing